A randomised controlled trial of oral prednisolone for viral-wheeze in pre-school children with stratification for serum level of Eosinophil Protein X (EPX)
Completed
- Conditions
- AsthmaRespiratory tract diseases: AsthmaRespiratory
- Registration Number
- ISRCTN78625210
- Lead Sponsor
- Record Provided by the NHS R&D 'Time-Limited' National Programme Register - Department of Health (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Children aged between 18 and 48 months of age presenting with viral-wheeze.
Exclusion Criteria
No exclusion criteria
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Outcome will be assessed by parental scoring of respiratory symptoms using a diary card.
- Secondary Outcome Measures
Name Time Method o secondary outcome measures
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link EPX levels to prednisolone efficacy in preschool viral wheeze?
How does oral prednisolone compare to inhaled corticosteroids in managing viral wheeze in pre-schoolers?
Do serum EPX levels predict response to prednisolone in viral wheeze or asthma subtypes?
What are the common adverse events of prednisolone in pre-schoolers and optimal management strategies?
Are there combination therapies with prednisolone for viral wheeze that improve outcomes over monotherapy?